Frostick S. Orally active antithrombotic agents: a new era in the prevention of VTE. Thrombus 2008; 13.1: 5

Thrombus

Reference list

Frostick S. Orally active antithrombotic agents: a new era in the prevention of VTE. Thrombus 2008; 13.1: 5–6.

1. 1. http://www.nice.org.uk/nicemedia/pdf/CG046NICEguideline.pdf

2. Eriksson B, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous theormboembolism after total hip replacement: a randomised, double blind, non-inferiority trial. Lancet 2007; 370: 949–956.

3. Eriksson B, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Throm Haemost 2007; 4: 2178–2185.

4. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med, 2008, 358, 2765–2775.

5. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31–39.

6. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–2785.

7. Turpie AGG, Lassen MR, Kakkar AK et al. Once-daily, oral rivaroxaban for the prevention of venous thromboembolism after major orthopaedic surgery. A pooled analysis of the RECORD1, 2, 3, and 4 studies. American Society of Hematology, San Francisco, Dec 6th – 9th 2008.

8. http://www.nice.org.uk/Guidance/TA157

9. http://www.nice.org.uk/Guidance/TA/Wave17/15

Published by Hayward Medical Communications